Clinical Trial - NCT02715284

Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Recruiting

Sponsor: Tesaro, Inc.

Collaborators:

Information provided by (Responsible party): Sponsor

ClinicalTrials.gov Identifier: NCT02715284

Protocol Info

Short Description: Phase 1 TSR-042 in Solid Tumors
Long Description: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors
MGH Status: Open
Sponsor: Tesaro
Disease Program: Phase I

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.




Purpose

This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs) of dostarlimab and will continue until the maximum tolerated dose (MTD) is reached or may be stopped at any dose level up to the highest dose of 20 milligrams per kilograms (mg/kg) based on emerging safety and PK/PDy data. Part 2 will be conducted in two subparts, Part 2A (fixed-dose safety evaluation cohorts) and Part 2B (expansion cohorts). Part 2A of the study will evaluate the safety and tolerability of dostarlimab at fixed doses of 500 mg administered every 3 weeks (Q3W) and 1000 mg administered every 6 weeks (Q6W). Part 2B of the study will examine the safety and clinical activity of dostarlimab in cohorts of participants with specific types of advanced solid tumors.
Condition Title Intervention Phase
Neoplasms Dostarlimab Phase 1
Study Type Interventional
Official Title A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Primary Outcome Measures

Part 1: Number of participants with treatment emergent AEs (TEAEs) [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with immune related AEs of interest [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal hematology parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal clinical chemistry parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal thyroid function [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal urine parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal vital signs [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal electrocardiogram (ECG) parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants with abnormal physical examination. [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Number of participants receiving concomitant medications [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with TEAEs [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with immune related AEs of interest [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal hematology parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal clinical chemistry parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal thyroid function [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal urine parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal vital signs [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal ECG [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants with abnormal physical examination [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2A: Number of participants receiving concomitant medications [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with TEAEs [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with immune related AEs of interest [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal hematology parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal clinical chemistry parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal thyroid function [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal urine parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal vital signs [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal ECG parameters [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants with abnormal physical examination [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Number of participants receiving concomitant medications [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A1 Overall Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort F ORR by RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A2 ORR by RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort G ORR by RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort E ORR by immune related Response Evaluation Criteria in Solid Tumors per irRECIST [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A1 Duration of response (DOR) [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort F Duration of response (DOR) [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A2 Duration of response (DOR) [Time Frame: Up to 2 years] [Designated as safety issue: ]


Secondary Outcome Measures

Part 2B: Cohort A1 ORR by independent blinded central review using RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort F ORR by independent blinded central review using RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A1 Immune-related objective response rate (irORR) by irRECIST [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A2 irORR by irRECIST [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort F irORR by irRECIST [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort G irORR by irRECIST [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A1 Duration of response (DOR) based on independent blinded central review using RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort F DOR based on independent blinded central review using RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort G DOR based on independent blinded central review using RECIST version 1.1 [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A1 Disease control rate [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort A2 Disease control rate [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort F Disease control rate [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Cohort G Disease control rate [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Immune related disease control rate [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Immune related duration of response [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Progression free survival [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 2B: Overall survival [Time Frame: Up to 2 years] [Designated as safety issue: ]

Part 1: Area under the concentration-time curve from time 0 to last (AUC,0-last) assessment of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504 and 672 hours post dose] [Designated as safety issue: ]

Part 1: Area under the concentration-time curve from time 0 to infinity (AUC, 0-infinity) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 1: Minimum concentration (Cmin) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 1: Maximum concentration (Cmax) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 1: Clearance (CL) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 1: Volume of distribution (Vz) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 1: Area under the concentration-time curve at steady state (AUC,ss) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 1: Minimum concentration at steady state (Cmin,ss) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose.] [Designated as safety issue: ]

Part 1: Maximum concentration at steady state (Cmax,ss) of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504,672 hours post dose] [Designated as safety issue: ]

Part 2A : AUC,0-last assessment of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: AUC, 0-infinity of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmin of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmax of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: CL of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504,hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: Vz of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years.] [Designated as safety issue: ]

Part 2A: AUC,ss of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmin,ss of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmax,ss of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, and 504 hours post dose Q3W upto 2 years] [Designated as safety issue: ]

Part 2A : AUC,0-last assessment of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: AUC, 0-infinity of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmin of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmax of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: CL of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: Vz of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: AUC,ss of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmin,ss of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840, and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2A: Cmax,ss of dostarlimab [Time Frame: Predose, 0.25, 0.5, 1.5, 3, 24, 48, 96, 168, 336, 504, 672, 840 and 1008 hours post dose Q6W upto 2 years] [Designated as safety issue: ]

Part 2B : AUC,0-last assessment of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: AUC, 0-infinity of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: Cmin of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: Cmax of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: CL of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: Vz of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: AUC,ss of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: Cmin,ss of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Part 2B: Cmax,ss of dostarlimab [Time Frame: Predose, 0.5 and 1.5 hours post dose] [Designated as safety issue: ]

Estimated Enrollment: 740
Study Start Date: March 2016
Estimated Study Completion Date: November 2023
Estimated Primary Completion Date: November 2023
Arms Assigned Interventions

Experimental:Part 1: Participants receiving dostarlimab

Part 1 will evaluate dostarlimab at ascending weight-based doses 1 mg/kg, 3 mg/kg and 10 mg/kg. Higher dose levels 15 mg/kg and/or 20 mg/kg may also be explored. Dostarlimab will be administered intravenously (IV) on Day 1 and Day 15 of each cycle; cycle length is 28 days. Cohorts will be enrolled sequentially and will initially follow a 3+3 design.
Biological:Dostarlimab
Dostarlimab (160 mg, 20 mg/mL; or 500 mg, 50 mg/mL) is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2). Dostarlimab will be administered via a 30 minute IV infusion on Day 1 and Day 15 of each cycle in Part 1. For additional patients enrolled specifically to better characterize the PK/PDy profile in Part 1, dostarlimab administration during Cycle 1 will only occur on Day 1 with the second dose administered on Cycle 2/Day 1 and Q2W thereafter. For Part 2A and 2B, dostarlimab will be administered on Day 1 of each treatment cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days.

Experimental:Part 2A: Participants receiving dostarlimab

In Part 2A, participants will receive fixed dose of 500 mg administered Q3W or 1000 mg administered Q6W dose on Day 1 of each cycle. Cycle duration for Q3W dosing is 21 days and Q6W dosing is 42 days. Cohorts will enroll participants with advanced solid tumor using a modified 6+6 design and will follow a 6+6 design.

Experimental:Part 2B: Cohort A1 dMMR/MSI-H

Part 2B: Cohort A1 will include participants with mismatch repair deficient microsatellite instability high (dMMR/MSI-H) endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >= IIIB) disease.

Experimental:Part 2B: Cohort A2 MMR-proficient/MSS endometrial cancer

Part 2B: Cohort A2 will include participants with MMR-proficient/MSS endometrial cancer who have progressed on or after platinum doublet therapy. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles. Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (Stage >=IIIB) disease.

Experimental:Part 2B: Cohort E NSCLC

Part 2B: Cohort E NSCLC will include participants with non-small cell lung cancer (NSCLC) who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.

Experimental:Part 2B:Cohort F non-endometrial dMMR/MSI-H & POLE-Mut cancers

Participants with recurrent or advanced dMMR/MSI-H solid tumors or polymerase É› mutated (POLE -mut) solid tumors , except endometrial cancers, that have progressed following up to 2 prior lines of systemic therapy for recurrent or advanced (>=Stage IIIB) disease and who have no alternative treatment options. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.

Experimental:Part 2B: Cohort G PROC without known BRCA

Participants with advanced, relapsed, high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer without known breast cancer susceptibility gene (BRCA) mutation who have platinum-resistant disease receiving dostarlimab and who have also been previously treated with bevacizumab. These participants will receive dostarlimab 500 mg for Q3W for the first 4 cycles followed by 1000 mg Q6W for all subsequent cycles.

Eligibility

Ages Eligible for Study: N/A-N/A

Genders Eligible for Study: All

Accepts Healthly Volunteers: No

Inclusion Criteria:

  • Participant is at least 18 years of age.
  • Participant has proven recurrent or advanced solid tumor and has disease progression after treatment with available anti cancer therapies, or is intolerant to treatment that meets the following requirements for the part of the study they will participate in:
  • a. Part 1: Any histologically or cytologically proven recurrent advanced solid tumor
  • b. Part 2A: : Any histologically or cytologically proven recurrent advanced solid tumor
  • c. Part 2B: Histologically of cytologically proven recurrent or advanced solid tumor with measurable lesion(s) per RECIST version 1.1 and meets one of the following disease types:
  • The criteria below should be met for participant participating in:
  • Cohort A1 (dMMR/MSI-H endometrial cancer) and
  • Cohort A2 (MMR-proficient/MSS endometrial cancer)
  • Participants who have progressed on or after platinum doublet therapy
  • Participants have received no more than 2 lines of anti-cancer therapy for recurrent or advanced (>=Stage IIIB) disease. Prior treatment with hormone therapies is acceptable and does not count towards the number of anti-cancer therapies noted in the criterion above for this cohort.
  • All endometrial cancer histologies are allowed except endometrial sarcoma (including carcinosarcoma).
  • Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD on or after the latest systemic anti-cancer therapy based on RECIST 1.1 to Central Radiology prior to the first dose of dostarlimab.
  • Presence of at least 1 measurable lesion on Baseline scan will be confirmed by central radiology review.
  • Status of tumor MMR/MSI: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participant with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to Cycle 1 Day 1 (C1D1). For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing.
  • Cohort E - Participants with NSCLC who progressed after at least 1 prior platinum-based systemic chemotherapy regimen for recurrent or advanced disease.
  • Chemotherapy regimen in the adjuvant or neoadjuvant setting following surgery and/or radiation is acceptable if recurrent or advanced disease develops within 6 months from completion of therapy.
  • Participants with a known epidermal growth factor receptor (EGFR) mutation must have received a chemotherapy regimen and an EGFR tyrosine-kinase inhibitor (TKI) (e.g., erlotinib, gefitinib, afatinib, or experimental)
  • Participants with a known anaplastic lymphoma kinase (ALK) translocation must have received a chemotherapy regimen and an ALK inhibitor (e.g., crizotinib, ceritinib or experimental)
  • Cohort F - Participants with recurrent or advanced dMMR/MSI-H solid tumors or POLE-mut solid tumors, except endometrial cancers, that have progressed following up to 2 prior lines of systemic therapy for recurrent or advanced (>=Stage IIIB) disease and who have no alternative treatment options. Prior treatment with hormone therapies alone given for recurrent or advanced disease is acceptable and does not count towards the number of anti-cancer therapies.
  • dMMR/MSI-H colorectal cancer (CRC) participants must have progressed after or been intolerant to treatment with fluoropyrimidine, oxaliplatin, and irinotecan. Progression following up to 3 prior lines of therapy is allowed.
  • Ovarian cancer participants with platinum-resistant disease (i.e., progression occurred <6 months on or after platinum doublet chemotherapy): receipt of up to 1 line of systemic therapy after becoming platinum-resistant is allowed.
  • Participants must submit 2 scans demonstrating increase in tumor measurement that meet criteria for PD based on RECIST 1.1 to Central Radiology prior to the first dose of dostarlimab.
  • Tumor MMR/MSI or POLE status: Participants can be screened based on local MMR/MSI testing results using immunohistochemistry (IHC), polymerase chain reaction (PCR), or next generation sequencing (NGS) performed in a certified local laboratory, but participant eligibility needs to be determined by MMR IHC results. For participants with available local MMR IHC results for the respective cohort(s), tumor samples have to be submitted to a central IHC laboratory and its quality has to be checked and cleared prior to C1D1. For participants without available local MMR IHC test results (participants with local PCR or NGS test results), central IHC results have to confirm eligibility prior to proceeding with other screening procedures. After the central IHC test is completed, remaining tumor tissue may be tested for further exploratory biomarkers or may be sent to a central NGS laboratory for further testing.
  • Participants who are considered for the study based on POLE mutation must have the local results available showing tumor mutation(s) in the exonuclease domain of the POLE gene (amino acid residues 268-471) to begin screening. Participants must have the quality of submitted tumor samples checked and cleared by a central IHC laboratory prior to receiving study treatment.
  • Cohort G: Participants must have recurrent high-grade serous, endometrioid, or clear cell ovarian, fallopian tube, or primary peritoneal cancer.
  • Participants must have presence of at least 1 measurable lesion on Baseline scan that will be confirmed by central radiology review.
  • Participants must be considered resistant to the last administered platinum therapy, that is, the time from the last administered platinum dose until the initial documented progression (as evidenced by radiographic progression per RECIST) must be less than 6 months.
  • Participants must have completed at least 1 but no more than 3 prior lines of therapy for advanced or metastatic ovarian cancer. Neoadjuvant, adjuvant, and the combination of both will be considered as 1 line of therapy. Treatment with single-agent bevacizumab given as maintenance is not counted as a separate line of therapy. If a therapeutic regimen is modified or changed for a reason other than lack of response or PD (such as allergic reaction, toxicity, or drug availability), this is not counted as a separate line of therapy. The use of single-agent hormonal therapy given for reasons other than PD per RECIST v1.1 (i.e., hormonal therapy given for increasing Cancer antigen [CA]-125 levels) is not counted as a separate line of therapy.
  • Participants must have been previously treated with platinum-based regimen, taxane agent(s), and bevacizumab (bevacizumab could be used as a single agent or in combination with another agent, in frontline therapy, as maintenance, or for treatment of recurrent disease).
  • Part 2B: Participants must have archival tumor tissue available that is formalin-fixed and paraffin-embedded.
  • For participants who do not have archival tissue, a new biopsy must be performed to obtain a tissue sample prior to study treatment initiation. For participants without available archival tissue, the biopsy should be taken from the tumor lesions (either primary or metastatic) that have easy accessibility and low biopsy-associated risks and will exclude biopsies of the liver, brain, lung/mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach or bowel.
  • For Cohort G, participant must provide formalin fixed paraffin embedded (FFPE) tumor tissue block(s) with sufficient tumor content (as confirmed by the Sponsor's designated central laboratory) during screening to enable, for example, measures of homologous recombination pathway defects and PD-L1 status. The use of slides created from paraffin-embedded tissue as opposed to FFPE blocks must be approved by the Sponsor.
  • Female participants must have a negative serum pregnancy test within 72 hours prior to the date of the first dose of study medication: unless they are of non-child bearing potential.
  • Non child bearing potential is defined as: >= 45 years of age and has not had menses for > 1 year; Amenorrheic for < 2 years without a hysterectomy and oophorectomy and have a follicle- stimulating hormone (FSH) value in the postmenopausal range upon pre-study (screening) evaluation. Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT) scan. Tubal ligation must be confirmed with medical records of the actual procedure.
  • Female participants of childbearing potential must agree to use 1 highly effective form of contraception with their partner starting with the screening visit through 150 days after the last dose of study therapy.
  • Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of <= 2 for Part 1 and <= 1 for Part 2.
  • Participant has an adequate organ function.

Exclusion Criteria

  • Participant has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent.
  • Participant has a known uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Participant has a known additional malignancy that progressed or required active treatment within the last 2 years. Exceptions include basal cell carcinoma of the skin, squamous cell cancer (SqCC) of the skin that has undergone potentially curative therapy, or in situ cervical cancer.
  • Participant is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study (including obtaining informed consent).
  • Participant is pregnant or breastfeeding, or expecting to conceive children within the projected duration of the study, starting with the Screening Visit through 150 days after the last dose of study treatment.
  • Participant has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
  • Participant has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).
  • Participant has a known active hepatitis B (eg, hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid (HCV RNA) (qualitative) is detected).
  • Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease- modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Use of inhaled steroids, local injection of steroids, and steroid eye drops are allowed.
  • Participant has as history of interstitial lung disease.
  • Participant has not recovered (i.e., to <= Grade 1 or to Baseline) from radiation- and chemotherapy-induced AEs or received transfusion of blood products (including platelets or red blood cells) or administration of colony-stimulating factors (including granulocyte-colony stimulating factor [G-CSF], granulocyte macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 3 weeks prior to the first dose of study drug.
  • Participant has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study drug.
  • Participant has received prior anti-cancer therapy (chemotherapy, targeted therapies, radiotherapy, or immunotherapy) within 21 days, or less than 5 times the half-life of the most recent therapy prior to study Day 1, whichever is shorter.
  • Participant has not recovered adequately (<= Grade 1) from AEs and/or complications from any major surgery prior to starting therapy.
  • Participant has received a live vaccine within 14 days of planned start of study therapy.
  • Participant has a known hypersensitivity to dostarlimab components or excipients.
  • For Cohort G, participants will not be eligible if they meet the following criteria:
  • Participants who experienced disease progression within 3 months (as evidenced by radiographic progression per RECIST) of first-line platinum therapy.
  • Participants with known deleterious or suspicious deleterious mutation in BRCA1 or BRCA2 genes (local testing permitted).
  • Participants has received prior therapy with a poly(adenosine diphosphate-ribose) polymerase (PARP)-1/PARP-2 inhibitor.
  • Participant has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, might interfere with the participant's participation for the full duration of the study treatment, or is not in the best interest of the participant to participate.
  • Participant is immunocompromised. Participants with splenectomy are allowed.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT02715284

Locations

  • United States, Alabama
    • GSK Investigational Site Birmingham, Alabama, United States, 35233
  • United States, Arizona
    • GSK Investigational Site Goodyear, Arizona, United States, 85338
    • GSK Investigational Site Phoenix, Arizona, United States, 85054
    • GSK Investigational Site Scottsdale, Arizona, United States, 85258
  • United States, Arkansas
    • GSK Investigational Site Fayetteville, Arkansas, United States, 72703
  • United States, California
    • GSK Investigational Site Encinitas, California, United States, 92024
    • GSK Investigational Site La Jolla, California, United States, 92093
    • GSK Investigational Site Los Angeles, California, United States, 90095
    • GSK Investigational Site Newport Beach, California, United States, 92663
    • GSK Investigational Site Orange, California, United States, 92868
    • GSK Investigational Site San Francisco, California, United States, 94115
    • GSK Investigational Site Santa Monica, California, United States, 90403
  • United States, District of Columbia
    • GSK Investigational Site Washington, District of Columbia, United States, 20007
  • United States, Florida
    • GSK Investigational Site Jacksonville, Florida, United States, 32224
    • GSK Investigational Site Miami, Florida, United States, 33136
    • GSK Investigational Site Tampa, Florida, United States, 33612
  • United States, Georgia
    • GSK Investigational Site Atlanta, Georgia, United States, 30322
    • GSK Investigational Site Augusta, Georgia, United States, 30912
  • United States, Illinois
    • GSK Investigational Site Chicago, Illinois, United States, 60637
  • United States, Kansas
    • GSK Investigational Site Westwood, Kansas, United States, 66205
  • United States, Maine
    • GSK Investigational Site Scarborough, Maine, United States, 04074
  • United States, Maryland
    • GSK Investigational Site Baltimore, Maryland, United States, 21231
  • United States, Massachusetts
    • GSK Investigational Site Boston, Massachusetts, United States, 02114
    • GSK Investigational Site Boston, Massachusetts, United States, 02215
  • United States, Michigan
    • GSK Investigational Site Detroit, Michigan, United States, 48201
  • United States, Minnesota
    • GSK Investigational Site Rochester, Minnesota, United States, 55905
  • United States, Missouri
    • GSK Investigational Site Kansas City, Missouri, United States, 64111
  • United States, New Mexico
    • GSK Investigational Site Farmington, New Mexico, United States, 87401
  • United States, New York
    • GSK Investigational Site Albany, New York, United States, 12208
    • GSK Investigational Site Brooklyn, New York, United States, 11203
    • GSK Investigational Site Jamaica, New York, United States, 11432
    • GSK Investigational Site New York, New York, United States, 10016
    • GSK Investigational Site New York, New York, United States, 10032
  • United States, North Carolina
    • GSK Investigational Site Charlotte, North Carolina, United States, 28204
  • United States, Ohio
    • GSK Investigational Site Cleveland, Ohio, United States, 44106
    • GSK Investigational Site Columbus, Ohio, United States, 43210
    • GSK Investigational Site Hilliard, Ohio, United States, 43026
  • United States, Oklahoma
    • GSK Investigational Site Oklahoma City, Oklahoma, United States, 73104
  • United States, Oregon
    • GSK Investigational Site Portland, Oregon, United States, 97239
  • United States, Pennsylvania
    • GSK Investigational Site Philadelphia, Pennsylvania, United States, 19104
    • GSK Investigational Site Philadelphia, Pennsylvania, United States, 19111
  • United States, Rhode Island
    • GSK Investigational Site Providence, Rhode Island, United States, 02905
  • United States, Tennessee
    • GSK Investigational Site Nashville, Tennessee, United States, 37232-7415
  • United States, Texas
    • GSK Investigational Site Dallas, Texas, United States, 75230
    • GSK Investigational Site Dallas, Texas, United States, 75290-9032
    • GSK Investigational Site Houston, Texas, United States, 77030
    • GSK Investigational Site San Antonio, Texas, United States, 78229
    • GSK Investigational Site San Antonio, Texas, United States, 78229
  • United States, Utah
    • GSK Investigational Site Salt Lake City, Utah, United States, 84112
  • United States, Virginia
    • GSK Investigational Site Charlottesville, Virginia, United States, 22903
  • United States, Washington
    • GSK Investigational Site Seattle, Washington, United States, 356460
    • GSK Investigational Site Seattle, Washington, United States, 98104
    • GSK Investigational Site Spokane Valley, Washington, United States, 99216
    • GSK Investigational Site Spokane, Washington, United States, 99202
    • GSK Investigational Site Spokane, Washington, United States, 99204
  • United States, West Virginia
    • GSK Investigational Site Morgantown, West Virginia, United States, 26506-9260
  • United States, Wisconsin
    • GSK Investigational Site Milwaukee, Wisconsin, United States, 53226
  • Canada, Alberta
    • GSK Investigational Site Calgary, Alberta, Canada, T2N 4N2
    • GSK Investigational Site Edmonton, Alberta, Canada, T6G 1Z2
  • Canada, British Columbia
    • GSK Investigational Site Kelowna, British Columbia, Canada, V1Y 5L3
    • GSK Investigational Site Vancouver, British Columbia, Canada, V5Z 4E6
  • Canada, Ontario
    • GSK Investigational Site Hamilton, Ontario, Canada, L8V 5C2
    • GSK Investigational Site London, Ontario, Canada, N6A 4L6
  • Canada, Quebec
    • GSK Investigational Site Montreal, Quebec, Canada, H2L 4M1
    • GSK Investigational Site Montreal, Quebec, Canada, H4A 3J1
  • Czechia,
    • GSK Investigational Site Horovice, , Czechia, 26831
    • GSK Investigational Site Praha 5, , Czechia, 150 05
    • GSK Investigational Site Zlin, , Czechia, 76001
  • Denmark,
    • GSK Investigational Site Copenhagen, , Denmark, DK- 2100
    • GSK Investigational Site Odense, , Denmark, 5000
  • France,
    • GSK Investigational Site Caen Cedex 05, , France, 14076
    • GSK Investigational Site Lille, , France, 59000
    • GSK Investigational Site Marseille Cedex 9, , France, 13273
    • GSK Investigational Site Paris cedex 12, , France, 75571
    • GSK Investigational Site Paris Cedex 15, , France, 75908
    • GSK Investigational Site Saint-Herblain, , France, 44805
    • GSK Investigational Site Villejuif Cedex, , France, 94805
  • Italy, Campania
    • GSK Investigational Site Napoli, Campania, Italy, 80131
  • Italy, Emilia-Romagna
    • GSK Investigational Site Modena, Emilia-Romagna, Italy, 41100
  • Italy, Lazio
    • GSK Investigational Site Roma, Lazio, Italy, 00144
  • Italy, Lombardia
    • GSK Investigational Site Milano, Lombardia, Italy, 20132
    • GSK Investigational Site Milano, Lombardia, Italy, 20133
    • GSK Investigational Site Milano, Lombardia, Italy, 20141
  • Italy, Veneto
    • GSK Investigational Site Verona, Veneto, Italy, 37134
  • Italy,
    • GSK Investigational Site MIlano, , Italy, 20133
  • Poland,
    • GSK Investigational Site Gdynia, , Poland, 81-519
    • GSK Investigational Site Lublin, , Poland, 20081
    • GSK Investigational Site Lublin, , Poland, 20090
    • GSK Investigational Site Olsztyn, , Poland, 10-513
    • GSK Investigational Site Olsztyn, , Poland, 10-561
    • GSK Investigational Site Torun, , Poland, 87-100
  • Spain,
    • GSK Investigational Site Barcelona, , Spain, 08025
    • GSK Investigational Site Barcelona, , Spain, 08036
    • GSK Investigational Site Barcelona, , Spain, 8035
    • GSK Investigational Site Girona, , Spain, 17007
    • GSK Investigational Site Girona, , Spain, 17007
    • GSK Investigational Site Madrid, , Spain, 28027
    • GSK Investigational Site Madrid, , Spain, 28040
    • GSK Investigational Site Madrid, , Spain, 28040
    • GSK Investigational Site Madrid, , Spain, 28046
    • GSK Investigational Site Madrid, , Spain, 28050
    • GSK Investigational Site Málaga, , Spain, 29010
    • GSK Investigational Site Pamplona, , Spain, 31008
    • GSK Investigational Site Santiago de Compostela, , Spain, 15706
    • GSK Investigational Site Sevilla, , Spain, 41013
    • GSK Investigational Site Valencia, , Spain, 46009
    • GSK Investigational Site Valencia, , Spain, 46010
    • GSK Investigational Site Zaragoza, , Spain, 50009
  • United Kingdom, Surrey
    • GSK Investigational Site Sutton, Surrey, United Kingdom, SM2 5PT
  • United Kingdom,
    • GSK Investigational Site Aberdeen, , United Kingdom, AB25 2ZN
    • GSK Investigational Site Headington, Oxford, , United Kingdom, OX3 7LE
    • GSK Investigational Site London, , United Kingdom, SE1 9RT
    • GSK Investigational Site London, , United Kingdom, SW3 6JJ
    • GSK Investigational Site London, , United Kingdom, W1G 6AD
    • GSK Investigational Site London, , United Kingdom, W1T 7HA
    • GSK Investigational Site Manchester, , United Kingdom, M20 4BX
    • GSK Investigational Site Newcastle upon Tyne, , United Kingdom, NE7 7DN

Sponsors and Collaborators

Tesaro, Inc.

More Information

No publications provided

Responsible Party: Sponsor
ClinicalTrials.gov Identifier: NCT02715284
Other Study ID Numbers: 4010-01-001
Study First Received:
Last Updated:
Health Authority:

Keywords provided by Tesaro, Inc.:

Metastatic solid tumors

Advanced solid tumors

anti-PD-1

TSR-042

Immunotherapy

PD-1

Endometrial

Non-small cell lung cancer, NSCLC

MSI-High

Dostarlimab

dMMR

Next Steps


If you are interested in this protocol or in other treatment options at Massachusetts General Hospital, please Request a Consultation.







ClinicalTrials.gov processed this data on September 03, 2020